TITLE

Review: Regular inhaled short-acting β[sub2]-agonists improve lung function in stable chronic obstructive pulmonary disease: COMMENTARY

AUTHOR(S)
Gibson, Peter G.
PUB. DATE
January 2004
SOURCE
ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a study regarding regular inhaled short acting β[sub2] agonists (ISABAs) for the management of stable chronic obstructive pulmonary disease (COPD), published in the 2003 issue of the journal "Thorax." COPD is defined as airflow limitation that is progressive, not fully reversible, and associated with an abnormal inflammatory response in the lungs. The drug and the delivery system are important. Although longer-acting bronchodilators may improve efficacy and compliance, they are more expensive. As for delivery systems, pressurized metered-dose inhalers are most cost-effective, and so we should resist the temptation to treat patients and their furniture with nebulized therapy in stable COPD.
ACCESSION #
12104545

 

Related Articles

  • Budesonide/Formoterol: A Viewpoint by Paul W. Jones. Jones, Paul W. // Drugs;2004, Vol. 64 Issue 4, p444 

    Budesonide/formoterol is a fixed-dose combination of the corticosteroid budesonide and formoterol, a long-acting J32-agonist, inhaled as a dry powder. Current guidelines for chronic obstructive pulmonary disease (COPD) recommend a long-acting p2-agonist for patients whose symptoms are not...

  • COMMENTARY. Ribas, J. // British Journal of Sports Medicine;Aor2006, Vol. 40 Issue 4, p366 

    The article comments on the paper "Use of β2 agonists in sport: are the present criteria right?," by J. Naranjo Orellana and colleagues in this issue. The findings show that the use of these drugs could provide the asthmatic athlete the chance of full breathing capacity without any extra...

  • Use of β2 agonists in sport: are the present criteria right? Naranjo^ Orellana, J.; Prada, R. A. Centeno; Márquez, M. D. Carranza // British Journal of Sports Medicine;Aor2006, Vol. 40 Issue 4, p363 

    Background: The regulations for doping control prohibit the use of β2 agonist bronchodilators (salbutamol, salmeterol, formoterol, and terbutaline) unless the subject follows the procedure known as abbreviated therapeutic use exemption (ATUE). Objective: To highlight how the interest in...

  • E merging Therapeutic Options for the Management of COPD. Reid, Debra J.; Pham, Nga T. // Clinical Medicine Insights: Circulatory, Respiratory & Pulmonary;2013, Issue 7, p7 

    Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators...

  • A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease. Sovani, Milind P; Whale, Christopher I.; Tattersfield, Anne. E // Drug Safety;2004, Vol. 27 Issue 10, p689 

    The two inhaled long-acting β2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease...

  • Budesonide/Formoterol: A Viewpoint by Michael Roth1,2. Michael Roth, Paul W. // Drugs;2004, Vol. 64 Issue 4, p443 

    This article presents views of the author on formoterol. Corticosteroids combined with long-acting J32-agonists, for example budesonide/formoterol, have been suggested for the treatment of inflammatory lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The...

  • Review: Regular inhaled short-acting β[sub2]-agonists improve lung function in stable chronic obstructive pulmonary disease.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p12 

    This article focuses on a study regarding regular inhaled short acting β[sub2] agonists (ISABAs) for the management of stable chronic obstructive pulmonary disease (COPD), published in the 2003 issue of the journal "Thorax." For this study the researchers selected studies if they were...

  • Discussion.  // Respiratory Care;May2008, Vol. 53 Issue 5, p623 

    The article presents a discussion of the paper "Safety and Efficacy of β agonists" by James F. Donohue. Donohue says he would not use short-acting β agonists regularly in asthma or chronic obstructive pulmonary disease, because there's a lot of loss of bronchial protection. Meanwhile, he...

  • Do inhaled beta-agonists control cough in URIs or acute bronchitis? Stephens, Mary Maniscalco; Nashelsky, Joan // Journal of Family Practice;Aug2004, Vol. 53 Issue 8, p662 

    This article presents a study, which seeks to examine whether inhaled beta-agonists control cough in upper respiratory infections or acute bronchitis. It notes that even without a history of lung disease, patients presenting with cough due to acute respiratory illness and with evidence of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics